数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约317.96万 元。 1月5日，广生堂涨5.04%，截至发稿，报93.64元/股，成交2.59亿元，换手率2.07%，总市值149.14亿 元。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 从广生堂十大流通股东角度 赵磊累计任职时间186天，现任基金资产总规模329.54亿元，任职期间最佳基金回报1.48%， 任职期间 最差基金回报-2.51%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that various segments within the pharmaceutical industry have seen multiple stocks with over 100% gains in 2025, particularly in the chemical preparation sector, which has outperformed due to the rise in valuations of innovative drugs and strong clinical data from pipelines [4][13] - The report anticipates continued opportunities in the innovative drug sector, driven by the global competitiveness of Chinese pharmaceutical companies and the recognition of their R&D capabilities by multinational corporations [5][14] - Emerging industries such as AI, brain-computer interfaces, and biomanufacturing are expected to gradually transform various segments of the pharmaceutical field, with ongoing efforts to identify investment opportunities within these areas [5][14] Summary by Sections 1. Performance of Pharmaceutical Segments - In 2025, the chemical preparation sector showed the best performance, with top stocks like Shuyou Shen, Guangsheng Tang, and Anglikang achieving over 100% gains due to favorable clinical data and valuation increases [4][13] - The bioproducts sector, including companies like Sanofi and Rongchang Biopharma, also saw significant gains driven by quality pipelines and business development opportunities abroad [4][13] - The pharmaceutical R&D outsourcing sector experienced a "Davis Double" effect, with companies like WuXi AppTec and Haoyuan Pharmaceutical reporting exceptional performance due to increased demand and exceeding expectations [4][13] 2. Market Trends and Weekly Performance - In the fifth week of December 2025, the pharmaceutical sector declined by 2.06%, underperforming the CSI 300 index by 1.47 percentage points, ranking 28th among 31 sub-industries [6][18] - The hospital sector had the smallest decline at 0.85%, while the offline pharmacy sector faced the largest drop at 4.11% [6][22] 3. Recommendations and Focus Areas - The report continues to recommend investment in the innovative drug sector and its supply chain, particularly in CXO and R&D services, as well as in emerging industries like AI and biomanufacturing [5][7][14] - Monthly and weekly stock recommendations include WuXi AppTec, Sanofi, and Haoyuan Pharmaceutical, among others, indicating a focus on companies with strong growth potential [7][15]

营商环境是企业生存发展的土壤，好的营商环境就是生产力、竞争力。 习近平总书记高度重视优化营商环境，2024年10月在福建考察时要求，"营造更加完善的创新环境、更 有吸引力的人才环境""坚持'两个毫不动摇'，创新发展'晋江经验'，充分激发全社会投资创业活力"。 在2025年2月17日召开的民营企业座谈会上，习近平总书记对如何优化营商环境提出了明确要求，体现 出鲜明的问题导向。 福建深入贯彻落实习近平总书记关于优化营商环境的重要论述和对福建工作的重要要求，深入实施新时 代民营经济强省战略，创新发展"晋江经验"，持续打造市场化、法治化、国际化、便利化一流营商环 境。 连续5年召开民营经济代表人士座谈会，召开全省优化营商环境大会，编制实施福建省首份营商环境建 设规划，出台优化营商环境条例、营商环境创新改革行动计划，营商环境总体满意率连续4年超85%， 一体化政务服务能力连续2年位列全国第一梯队……高位推动、系统推进，福建正驰而不息打造一方近 悦远来的营商沃土，切实担起经济大省挑大梁的重大责任、勇争推动高质量发展之先。 知势谋远 驰而不息培优营商土壤 去年1月，全省首单民营企业公募REITs——易方达华威市场REIT在 ...

Group 1 - The core viewpoint of the news is that Guangshentang's stock has shown significant volatility, with a year-to-date increase of 173.77%, but recent trends indicate a decline over the past 20 and 60 days [1] - As of December 24, Guangshentang's stock price was 89.44 yuan per share, with a market capitalization of 14.245 billion yuan [1] - The company has seen a net inflow of main funds amounting to 471,200 yuan, with significant buying activity from large orders [1] Group 2 - As of September 30, the number of shareholders for Guangshentang increased by 125.95% to 45,800, while the average number of circulating shares per person decreased by 55.74% to 2,985 shares [2] - For the period from January to September 2025, Guangshentang reported an operating income of 316 million yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million yuan, down 57.96% year-on-year [2] - Since its A-share listing, Guangshentang has distributed a total of 84.6485 million yuan in dividends, with no dividends paid in the last three years [3]

Market Performance - The chemical pharmaceutical sector increased by 1.95% on December 19, with XinNuoWei leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Top Gainers in Chemical Pharmaceutical Sector - XinNuoWei (300765) closed at 34.69, up 11.44%, with a trading volume of 311,700 shares and a transaction value of 1.069 billion [1] - KangYi Pharmaceutical (300086) closed at 11.02, up 11.43%, with a trading volume of 965,500 shares and a transaction value of 1.018 billion [1] - MuNanHai Pharmaceutical (000566) closed at 7.24, up 10.03%, with a trading volume of 1,325,900 shares and a transaction value of 914 million [1] Market Capital Flow - The chemical pharmaceutical sector saw a net inflow of 68.1822 million from institutional investors, while retail investors contributed a net inflow of 31.3 million [2] - The sector experienced a net outflow of 381 million from speculative funds [2] Individual Stock Capital Flow - ST Renfu (600079) had a net inflow of 92.7508 million from institutional investors, while it faced a net outflow of 26.4283 million from speculative funds [3] - GuangShengTang (300436) recorded a net inflow of 49.2520 million from institutional investors, with a net outflow of 17.4322 million from speculative funds [3] - KangZhi Pharmaceutical (300086) had a net inflow of 28.1873 million from institutional investors, while it faced a net outflow of 3.1280 million from retail investors [3]

12月19日，广生堂涨5.02%，截至发稿，报90.63元/股，成交2.48亿元，换手率2.05%，总市值144.34亿 元。 责任编辑：小浪快报 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模1375.12万。今年以来收益11.87%， 同类排名5281/8098；近一年收益6.25%，同类排名6196/8067；成立以来亏损54.1%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 截至发稿，马毅累计任职时间11年278天，现任基金资产总规模27.18亿元，任职期间最佳基金回报 42.13%， 任职期间最差基金回报-5.55%。 麦健沛累计任职时间222天，现任基金资产总规模2.31亿元，任职期间最佳基金回报20.94%， 任职期间 最差基金回报-5.55%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号 ...

广生堂（300436.SZ）12月3日在投资者互动平台表示，尊敬的投资者，您好！GST-HG141的III期临床试 验是一项48周治疗的随机双盲研究，是公司创新药研发管线的重点项目，正按计划全力推进。为确保数 据的完整性，公司目前暂未安排该试验中期揭盲分析计划。公司将持续高效推进试验进程并及时披露创 新药重大进展，感谢您的关注和支持！ （记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：请问广生堂141三期临床会不会出中期数据？如果会的 话大概在什么时候出？ ...

Core Viewpoint - Guangshentang experienced a decline of 5.01% on December 2, with a stock price of 94.54 CNY per share and a total market capitalization of 15.057 billion CNY [1] Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015 [1] - The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications and 1.46% from other supplementary products [1] Fund Holdings - Jin Xin Fund has one fund heavily invested in Guangshentang, specifically the Jin Xin Value Selection Mixed A (005117), which held 11,000 shares, accounting for 3.65% of the fund's net value, ranking as the eighth largest holding [2] - The fund has experienced a floating loss of approximately 54,900 CNY today [2] Fund Performance - Jin Xin Value Selection Mixed A (005117) was established on September 1, 2017, with a current scale of 13.4048 million CNY [2] - Year-to-date return is 52.18%, ranking 741 out of 8122 in its category; the one-year return is 47.38%, ranking 869 out of 8056; and since inception, the return is 70.76% [2] Fund Manager Information - The fund managers are Liu Shang and Tan Zhiming, with Liu having a tenure of 102 days and a total fund size of 109 million CNY, while Tan has a tenure of 237 days with a total fund size of 141 million CNY [3] - Liu's best and worst fund returns during his tenure are -7.2% and -14.03%, respectively, while Tan's best and worst returns are 33.16% and -2.98% [3]

Core Insights - The article highlights the increasing participation of foreign institutional investors (QFII/RQFII) in private placements of A-share companies, exemplified by Estun's recent fundraising efforts [1][2][4] Group 1: Estun's Private Placement - Estun issued 28,392,900 shares to seven subscription entities, including major foreign investors like JPMorgan Chase and Morgan Stanley [1][2] - The total fundraising amount for Estun's private placement was 795 million yuan [2] - The share allocation included 4.64 million shares to JPMorgan Chase, 4.60 million shares to Morgan Stanley, and 468,600 shares to Allianz Global Investors Singapore, with respective investments of 130 million yuan, 129 million yuan, and 13.12 million yuan [2] Group 2: Broader Trend of Foreign Participation - Over the past month, more than ten listed companies have attracted significant foreign investment in their private placements, indicating a broader trend [1][3] - Companies like Xiaokang and Huichuan Technology also saw substantial foreign participation, with JPMorgan Chase investing 200 million yuan in Xiaokang and Hillhouse Capital investing 400 million yuan in Huichuan Technology [2][3] Group 3: Impact of Regulatory Changes - Recent regulatory changes by the China Securities Regulatory Commission and other authorities have lowered the investment barriers for QFII/RQFII, facilitating foreign investment in A-shares [4] - The strong recovery of the Chinese economy and the upward trend in the capital market have further enhanced the attractiveness of A-shares for foreign investors [4] Group 4: Performance of Participating Companies - The article notes that the stock prices of companies involved in private placements have generally performed well post-issuance, leading to significant unrealized gains for foreign investors [4][5] - Specific examples include Estun's placement price of 28 yuan per share, with a current price of 38.97 yuan, and Huichuan Technology's placement price of 58 yuan, now at 80.78 yuan [5]

关于选举第五届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章 程指引》《关于新＜公司法＞配套制度规则实施相关过渡期安排》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》（等有关法律、法规和规范性文件的规定，结合公司 实际情况，公司于 2025 年 11 月 21 日召开了 2025 年第三次临时股东大会，审议 通过了《关于修订＜公司章程＞的议案》，根据修订后的《福建广生堂药业股份 有限公司章程》（以下简称"《公司章程》"），董事会由 9 名董事组成，设董 事长 1 人，独立董事 3 人，职工代表董事 1 人。 公司于 2025 年 11 月 21 日召开了职工代表大会，经与会职工代表认真讨论， 一致同意选举欧阳昭权先生（简历详见附件）为公司第五届董事会职工代表董事， 与其他现任董事共同组成公司第五届董事会，任期自本次职工代表大会选举通过 之日起至第五届董事会任期届满之日止。 欧阳昭权先生符合《公司法》等 ...